Chimerix

Chimerix appoints Michael Rogers as chief development officer

Monday, March 18, 2013 09:40 AM

Chimerix, a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, has appointed Michael D. Rogers, Ph.D., as chief development officer.

More... »

FDA grants Fast Track to Chimerix’s CMX001 for cytomegalovirus infection

Wednesday, March 13, 2013 12:06 PM

The FDA has granted Fast Track designation for CMX001 for the prevention of cytomegalovirus (CMV) infection, according to Chimerix, the drug’s developer. CMX001 is the company's broad spectrum, oral nucleotide analog lipid-conjugate that blocks replication of double-stranded DNA (dsDNA) viruses.

More... »

Ernest Mario named chairman of Chimerix

Wednesday, February 20, 2013 12:25 PM

Chimerix, a Durham, N.C.-based biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, has appointed Ernest Mario, Ph.D., as chairman of its board of directors.

More... »

Chimerix appoints Michelle Berrey as CMO

Monday, November 19, 2012 10:45 AM

Chimerix, a Durham, N.C.-based biotechnology company developing orally-available antiviral therapeutics, has appointed Michelle Berrey, MD, MPH, as chief medical officer.

More... »

Syndax appoints Pappas to board of directors

Friday, April 6, 2012 03:26 PM

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company based in Waltham, Mass., has added Arthur M. Pappas to the ranks of its board of directors.

More... »

Chimerix launches AdV HALT trial

Friday, July 15, 2011 10:21 AM

Chimerix, a biotechnology company, has begun patient dosing in the AdV HALT trial.  The FDA has granted CMX001 Fast Track designation status for the development program for this indication.

More... »

Chimerix appoints Timothy Trost senior VP, CFO

Tuesday, March 29, 2011 12:06 PM

Chimerix, a pharmaceutical company developing oral antiviral therapeutics, has named Timothy W. Trost senior vice president and chief financial officer.

More... »